Development Level

Tchem 9 | 1,598
Tbio 2 | 11,445

Collection

Kinase: IDG Consortium (Target... 1 | 125

IMPC Phenotype

abnormal behavior 2 | 298
decreased eosinophil cell numb... 1 | 24
decreased grip strength 1 | 116
decreased large unstained cell... 1 | 11
decreased leukocyte cell numbe... 1 | 73
decreased lymphocyte cell numb... 1 | 83
decreased neutrophil cell numb... 1 | 42
increased mean platelet volume 1 | 45
increased total body fat amoun... 1 | 134
polycystic kidney 1 | 15

Disease

Carcinoma 10 | 11,493
glioblastoma 8 | 5,792
osteosarcoma 7 | 7,950
ovarian cancer 7 | 8,520
psoriasis 7 | 6,694
Cancer 6 | 2,499
adult high grade glioma 6 | 3,801
atypical teratoid / rhabdoid tumor 6 | 5,112
group 3 medulloblastoma 6 | 4,104
lung cancer 5 | 4,740
Astrocytoma, Pilocytic 4 | 3,081
Breast cancer 4 | 3,578
ductal carcinoma in situ 4 | 1,745
ependymoma 4 | 4,679
invasive ductal carcinoma 4 | 2,951
malignant mesothelioma 4 | 3,232
medulloblastoma, large-cell 4 | 6,241
subependymal giant cell astrocytoma 4 | 2,287
breast carcinoma 3 | 1,638
colon cancer 3 | 1,478
intraductal papillary-mucinous neoplasm (IPMN) 3 | 3,291
lung carcinoma 3 | 2,843
nasopharyngeal carcinoma 3 | 1,058
oligodendroglioma 3 | 2,850
pituitary cancer 3 | 1,972
primitive neuroectodermal tumor 3 | 3,035
ulcerative colitis 3 | 1,819
Alzheimer's disease 2 | 658
Animal Mammary Neoplasms 2 | 136
Breast Neoplasms 2 | 445
Chronic Lymphocytic Leukemia 2 | 262
Colonic Neoplasms 2 | 142
Depressive disorder 2 | 409
Kidney cancer 2 | 2,613
Mammary Neoplasms 2 | 425
Mammary Neoplasms, Animal 2 | 136
Mammary Neoplasms, Experimental 2 | 154
Parkinson's disease 2 | 392
Pick disease 2 | 1,894
Prostatic Neoplasms 2 | 495
Splenomegaly 2 | 190
Weight decreased 2 | 103
acute myeloid leukemia 2 | 783
adrenocortical carcinoma 2 | 1,428
diabetes mellitus 2 | 1,728
fibroadenoma 2 | 559
intraductal papillary-mucinous adenoma (IPMA) 2 | 2,955
intraductal papillary-mucinous carcinoma (IPMC) 2 | 2,989
pancreatic cancer 2 | 2,398
tuberculosis 2 | 2,010
Abnormal brain FDG positron emission tomography 1 | 9
Aggressive systemic mastocytosis 1 | 20
Apathy 1 | 16
Apraxia 1 | 26
Apraxias 1 | 27
Autosomal recessive limb-girdle muscular dystrophy type 2B 1 | 5
Behavioral variant of frontotemporal dementia 1 | 8
Bone Marrow Diseases 1 | 7
Brain Neoplasms 1 | 33
Chronic Myelocytic Leukemia Accelerated Phase 1 | 59
Chronic phase chronic myeloid leukemia 1 | 45
Compulsive hoarding 1 | 7
Developmental arithmetic disorder 1 | 8
Difficulty making arithmetical calculations 1 | 8
Diplopia 1 | 8
Dysphasia 1 | 23
EEG with continuous slow activity 1 | 7
Echolalia 1 | 12
Excess nuchal skin 1 | 30
Frontotemporal cerebral atrophy 1 | 8
Hemangiosarcoma 1 | 18
Hormone receptor positive malignant neoplasm of breast 1 | 10
Hyperorality 1 | 7
Hyperphagia 1 | 23
Increased appetite (finding) 1 | 23
Irritation - emotion 1 | 68
Learning Disorders 1 | 29
Lymphoma, Mantle-Cell 1 | 11
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse 1 | 12
Mast cell leukemia 1 | 13
Memory Disorders 1 | 40
Morphological abnormality of the pyramidal tract 1 | 12
Mutism 1 | 17
Myeloma, Multiple 1 | 6
Neoplasms, Experimental 1 | 40
Neurodegenerative Diseases 1 | 38
Neurofibrillary degeneration (morphologic abnormality) 1 | 9
Peptic Ulcer 1 | 27
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia 1 | 45
Primary hyperparathyroidism 1 | 5
Primitive reflexes (palmomental, snout, glabellar) 1 | 7
Pyramidal sign 1 | 29
Pyramidal tract disease 1 | 12
Repeated speech 1 | 9
Restlessness 1 | 14
Restrictive behavior 1 | 7
Restrictive behavior, interests, and activities 1 | 7
Supranuclear gaze palsy 1 | 6
Urologic Neoplasms 1 | 8
Zollinger-Ellison syndrome 1 | 18

Tissue

Blood and immune system 11 | 16,909
Cardiovascular System 11 | 15,192
Digestive Tract 11 | 17,369
Endocrine System 11 | 18,159
Female tissues 11 | 17,400
Liver and Pancreas 11 | 16,750
Male tissues 11 | 17,142
Nervous System 11 | 16,725
Respiratory system 11 | 16,393
Skin and soft tissues 11 | 17,230
Urinary Tract 11 | 16,678

Target Family

Kinase 7 | 634
Non-IDG 4 | 12,091

PathwayCommons: pid Pathway

http://pathwaycommons.org/pc2/... 11 | 11
http://pathwaycommons.org/pc2/... 137 | 137
http://pathwaycommons.org/pc2/... 125 | 125
http://pathwaycommons.org/pc2/... 102 | 102
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 85 | 85
http://pathwaycommons.org/pc2/... 82 | 82
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 77 | 77
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 69 | 69
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 62 | 62
http://pathwaycommons.org/pc2/... 61 | 61
http://pathwaycommons.org/pc2/... 60 | 60
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 58 | 58
http://pathwaycommons.org/pc2/... 57 | 57
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 55 | 55
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 51 | 51
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 44 | 44
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 41 | 41
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 36 | 36

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Alpha-1-syntrophin SNTA1 Tbio Non-IDG -1.49227 31.4 254
Mitogen-activated protein kinase kinase kinase 20 MAP3K20 Tchem Kinase -1.18567 14.9 215
Eukaryotic elongation factor 2 kinase EEF2K Tchem Kinase -1.33559 25.1 319
Dual specificity mitogen-activated protein kinase kinase 3 MAP2K3 Tchem Kinase -2.35301 190.9 1060
Serine/threonine-protein kinase N1 PKN1 Tchem Kinase -2.03368 117.6 153
Stathmin STMN1 Tbio Non-IDG -2.90296 824.2 1052
Mitogen-activated protein kinase 12 MAPK12 Tchem Kinase -1.95173 88.4 378
Dual specificity mitogen-activated protein kinase kinase 6 MAP2K6 Tchem Kinase -2.01763 74.4 636
G1/S-specific cyclin-D1 CCND1 Tchem Non-IDG -3.82232 5737.3 1312
Mitogen-activated protein kinase 13 MAPK13 Tchem Kinase -2.63128 394.0 648